Journal
PHARMACOLOGY & THERAPEUTICS
Volume 221, Issue -, Pages -Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.pharmthera.2020.107753
Keywords
Tumor microenvironment; Target; Therapy; Drug; Resistance
Categories
Funding
- National Institutes of Health (NIH) [R01-CA112567-06, R01CA184836, R01CA208213]
- Duncan Family Institute Seed Funding Research Program
- METAvivor Research Award [56675]
- NIH Cancer CenterSupport Grant [P30CA016672]
Ask authors/readers for more resources
This article summarizes the current progress in targeting the tumor microenvironment in both drug development and clinical trials, emphasizing the challenges in intervening in the tumor microenvironment and discussing strategies to maximize therapeutic benefits. New technologies and approaches to better understand the tumor microenvironment are explored in this context.
Tumor microenvironment denotes the non-cancerous cells and components presented in the tumor, including molecules produced and released by them. The constant interactions between tumor cells and the tumor micro environment play decisive roles in tumor initiation, progression, metastasis, and response to therapies. The tumor microenvironment as a therapeutic target in cancer has attracted great research and clinical interest. Here we summarize the current progress in targeting the tumor microenvironment in both drug development and clinical trials; highlight challenges in targeting the tumor microenvironment to achieve therapeutic efficacy; explore new technologies and approaches to better decipher the tumor microenvironment; and discuss strategies to intervene in the pro-tumor microenvironment and maximize therapeutic benefits. Published by Elsevier Inc.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available